

Amendment to the Claims:

This listing of claims shall replace all prior versions and listing of claims in the application.

Listing of claims:

Claims 1-24 (canceled)

Claim 25: (pending) An isolated protein comprising amino acid residues 27 to 111 of SEQ ID NO:164.

Claim 26: (pending) The isolated protein of claim 25 which comprises amino acid residues 2 to 111 of SEQ ID NO:164.

Claim 27: (pending) The isolated protein of claim 25 which comprises amino acid residues 1 to 111 of SEQ ID NO:164.

Claim 28: (pending) The protein of claim 25 which further comprises a heterologous polypeptide sequence.

Claim 29: (pending) A composition comprising the protein of claim 25 and a pharmaceutically acceptable carrier.

Claim 30: (pending) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 25 by a cell; and
(b) recovering said protein.

Claim 31: (pending) An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HHTLF25 cDNA contained in ATCC Deposit No. 209125.

Claim 32: (pending) The isolated protein of claim 31 which comprises the amino acid sequence of the complete polypeptide encoded by the HHTLF25 cDNA contained in ATCC Deposit No. 209125, excepting the N-terminal methionine.

Claim 33: (pending) The isolated protein of claim 31 which comprises the amino acid sequence of the complete polypeptide encoded by the HHTLF25 cDNA contained in ATCC Deposit No. 209125.

Claim 34: (pending) The protein of claim 31 which further comprises a heterologous polypeptide sequence.

Claim 35: (pending) A composition comprising the protein of claim 31 and a pharmaceutically acceptable carrier.

Claim 36: (pending) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 31 by a cell; and
(b) recovering said protein.

Claim 37: (currently amended) An isolated protein comprising a polypeptide sequence which is at least 90% identical to amino acid residues 27 to 111 of SEQ ID NO:164, wherein said protein can induce the production of IL-10.

Claim 38: (pending) The isolated protein of claim 37, wherein said polypeptide sequence is at least 90% identical to amino acid residues 1 to 111 of SEQ ID NO:164.

Claim 39: (pending) The isolated protein of claim 37, wherein said polypeptide sequence is at least 95% identical to amino acid residues 27 to 111 of SEQ ID NO:164.

Claim 40: (pending) The isolated protein of claim 37, wherein said polypeptide sequence is at least 95% identical to amino acid residues 1 to 111 of SEQ ID NO:164.

Claim 41: (pending) The protein of claim 37 which further comprises a heterologous polypeptide sequence.

Claim 42: (pending) A composition comprising the protein of claim 37 and a pharmaceutically acceptable carrier.

Claim 43: (pending) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 37 by a cell; and
(b) recovering said protein.

Claim 44: (currently amended) An isolated protein comprising a polypeptide sequence which is at least 90% identical to the secreted portion of the polypeptide encoded by the

HHTLF25 cDNA contained in ATCC Deposit No. 209125, wherein said protein can induce the production of IL-10.

Claim 45: (pending) The isolated protein of claim 44, wherein said polypeptide sequence is at least 90% identical to the complete polypeptide encoded by the HHTLF25 cDNA contained in ATCC Deposit No. 209125.

Claim 46: (pending) The isolated protein of claim 44, wherein said polypeptide sequence is at least 95% identical to the secreted portion of the polypeptide encoded by the HHTLF25 cDNA contained in ATCC Deposit No. 209125.

Claim 47: (pending) The isolated protein of claim 44, wherein said polypeptide sequence is at least 95% identical to the complete polypeptide encoded by the HHTLF25 cDNA contained in ATCC Deposit No. 209125.

Claim 48: (pending) The protein of claim 44 which further comprises a heterologous polypeptide sequence.

Claim 49: (pending) A composition comprising the protein of claim 44 and a pharmaceutically acceptable carrier.

Claim 50: (pending) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 44 by a cell; and
(b) recovering said protein.

Claim 51: (currently amended) An isolated protein consisting of ~~at least 30 contiguous amino acid residues~~ a fragment of amino acid residues 27 to 111 of SEQ ID NO:164, wherein said fragment is at least 30 contiguous amino acid residues in length.

Claim 52: (currently amended) The isolated protein of claim 51 which consists of ~~at least 50 contiguous amino acid residues~~ a fragment of amino acid residues 27 to 111 of SEQ ID NO:164, wherein said fragment is at least 50 contiguous amino acid residues in length.

Claim 53: (pending) The protein of claim 51 which further comprises a heterologous polypeptide sequence.

Claim 54: (pending) A composition comprising the protein of claim 51 and a pharmaceutically acceptable carrier.

Claim 55: (pending) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 51 by a cell; and
(b) recovering said protein.

Claim 56: (currently amended) An isolated protein consisting of ~~at least 30 contiguous amino acid residues~~ a fragment of the secreted portion of the polypeptide encoded by the HHTLF25 cDNA contained in ATCC Deposit No. 209125, wherein said fragment is at least 30 contiguous amino acid residues in length.

Claim 57: (currently amended) The isolated protein of claim 56 which consists of ~~at least 50 contiguous amino acid residues~~ a fragment of the secreted portion of the polypeptide encoded by the HHTLF25 cDNA contained in ATCC Deposit No. 209125, wherein said fragment is at least 50 contiguous amino acid residues in length.

Claim 58: (pending) The protein of claim 56 which further comprises a heterologous polypeptide sequence.

Claim 59: (pending) A composition comprising the protein of claim 56 and pharmaceutically acceptable carrier.

Claim 60: (pending) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 56 by a cell; and
(b) recovering said protein.

Claim 61: (currently amended) An isolated protein consisting of ~~at least 30 contiguous amino acid residues~~ a fragment of amino acid residues 1 to 111 of SEQ ID NO:164, wherein said fragment is at least 30 contiguous amino acid residues in length

Claim 62: (currently amended) The isolated protein of claim 61 which consists of ~~at least 50 contiguous amino acid residues~~ a fragment of amino acid residues 1 to 111 of SEQ ID NO:164, wherein said fragment is at least 50 contiguous amino acid residues in length.

Claim 63: (pending) The protein of claim 61 which further comprises a heterologous polypeptide sequence.

Claim 64: (pending) A composition comprising the protein of claim 61 and a pharmaceutically acceptable carrier.

Claim 65: (pending) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 61 by a cell; and
(b) recovering said protein.

Claim 66: (currently amended) An isolated protein consisting of at least 30 contiguous amino acid residues a fragment of the complete polypeptide encoded by the HHTLF25 cDNA contained in ATCC Deposit No. 209125, wherein said fragment is at least 30 contiguous amino acid residues in length.

Claim 67: (currently amended) The isolated protein of claim 66 which consists of at least 50 contiguous amino acid residues a fragment of the complete polypeptide encoded by the HHTLF25 cDNA contained in ATCC Deposit No. 209125, wherein said fragment is at least 50 contiguous amino acid residues in length.

Claim 68: (pending) The protein of claim 66 which further comprises a heterologous polypeptide sequence.

Claim 69: (pending) A composition comprising the protein of claim 66 and pharmaceutically acceptable carrier.

Claim 70: (pending) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 66 by a cell; and
(b) recovering said protein.